Korean J Pediatr Infect Dis.  2008 Dec;15(2):108-114. 10.14776/kjpid.2008.15.2.108.

The Japanese Encephalitis Vaccine: Worldwide and Korean Status

• Hong YJ

• KMID: 2439920
• DOI: http://doi.org/10.14776/kjpid.2008.15.2.108

Abstract

Japanese encephalitis is the leading cause of viral encephalitis in Asia, where it accounts for up to 50,000 cases. Approximately 20% of affected patients die, and 30-50% of survivors have significant neurological sequelae. Inactivated mouse-brain derived Japanese encephalitis vaccines has been effectively implemented to control the disease effectively in Korea and several other Asian countries. However, the vaccine is expensive and difficult to produce, requires multiple doses, and has been associated with hypersensitivity reactions and rare adverse neurologicale events. The live-attenuated SA14-14-2 vaccine derived from primary hamster kidney (PHK) cells was developed in China and has been used there since 1988. Outside China, it has been licensed and used in Korea and several other Asian countries. This vaccine is effective and inexpensive. However, the lack of precedence for using a PHK cell substrate in a live-attenuated vaccine is a special issue of concern. The WHO working group has recommended additional safety studies in selected high-risk groups, as well as ongoing post-marketing studies to ensure long-term safety. Recently, a new inactivated vaccine and live-attenuated chimeric vaccine have been developed from vero cells. With this background, this article summarized the current status of Japanese encephalitis vaccination worldwide and in Korea.

Keyword

Japanese encephalitis; Inactivated and live-attenuated vaccine

MeSH Terms

Animals
Asia
Asian Continental Ancestry Group*
China
Cricetinae
Encephalitis, Japanese*
Encephalitis, Viral
Humans
Hypersensitivity
Japanese Encephalitis Vaccines
Kidney
Korea
Survivors
Vaccination
Vero Cells
Japanese Encephalitis Vaccines